Usana Health Sciences (USNA) Cash & Equivalents (2010 - 2026)

Usana Health Sciences (USNA) has 17 years of Cash & Equivalents data on file, last reported at $162.8 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 9.39% year-over-year to $162.8 million in Q2 2026; TTM through Apr 2026 was $162.8 million, a 9.39% decrease from a year earlier, with the FY2026 full-year figure at $158.4 million, down 12.87% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $162.8 million, up from $158.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for USNA reached as high as $364.9 million in Q3 2024 and fell as low as $145.3 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $249.0 million across 5 years, with a median of $243.4 million in 2022.
• Across the five-year window, Cash & Equivalents jumped 30.3% in 2023 and plunged 60.17% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $288.4 million in 2022, then grew by 14.56% to $330.4 million in 2023, then slumped by 44.99% to $181.8 million in 2024, then retreated by 20.04% to $145.3 million in 2025, then rose by 11.97% to $162.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $162.8 million in Q2 2026, $158.4 million in Q1 2026, and $145.3 million in Q3 2025.